Planning for supply chain resilience
Engagement-based strategy could increase resilience of pharma supply chain.
The COVID-19 pandemic cast a spotlight on pre-existing vulnerabilities in pharmaceutical supply chains, as well as creating new issues. Now as the world recovers, longer lead times, shipping disruptions, product shortages, and rising costs continue to impact the sector.
This was the subject of the presentation ‘Where’s the Sugar’ by Tom Wilson, Global Business Development Lead at Pfizer CentreOne, during CPHI North America last week. Wilson used the analogy of baking a cake and lacking the requisite ingredients to describe disruptions to pharmaceutical supply chains.
He said: ‘When we think about the supply chain challenges that we’re facing right now, our expectation is that these challenges are going to be with us for a while. And it may not be the same challenge this month that it was a year ago. It may not be the same challenge a year from now or two years from now, but we do think there’s a great disruption taking place.’
Wilson noted that disruptions are occurring in regional and global supply chains, are exacerbated by a shortfall in the talent marketplace, and cannot be remedied by simple solutions.
He advised building resilience into supply chains by formulating an effective strategy, adding that this allows organisations to remain ‘agile and nimble’.
‘If you understand your systems, you have the ability to know where your opportunities are in that system. You know where your risk factors are in that system, and you can adapt and mitigate to both,’ he said.
Wilson noted that organisations can choose to adopt one of two main operating models – a procurement-based model or an engagement-based model.
Wilson believes an engagement-based model, which hinges on transparency and fluid communication, allows for greater adaptability.
What this entails, according to Gallup Supplier Engagement research, is that companies adopt a proactive approach to measuring and managing the emotional connections that drive supplier engagement. Research indicates that companies who do this can reap substantial economic gains - including higher quality, improved planning, improved product development, greater supplier support and value, and lower costs.
‘The higher the degree of complexity, the higher the degree of specialisation, and the higher your value proposition is - then the engagement model is really something to strongly consider,’ Wilson advised, adding that if patients are ‘truly jeopardised by a disruption in supply, the engagement model is probably the way to go.’
A procurement-based model may work best for commodity purchases and off-the-shelf products, though Wilson noted that organisations would be well placed to have ‘a couple of source nodes when it comes to commodities.’
He recommended that companies assess which model most appropriately fits the organisation’s goals.
‘I’ve always said I wish I had a magic wand for the times I can’t get something. There are no magic wands,’ he said.
‘So it’s the more you know about your supply chain, the more you plan your supply chain – that enables you to understand where you can influence the supply chain. If you know where your risks are, you probably also know where your opportunities are.’
Finally, Wilson encouraged stakeholders across the supply chain to place patient impact front and centre, concluding: ‘There’s a patient at the end of every one of our supply chains and we should never forget that.’
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance